BCR signaling is a major driver in vivo, and there is also compelling evidence that CD40 and additional signaling is involved in CLL proliferation and drug resistance [2, 3, 6, 7, 13, 39–41]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.